advertisement
 

  Back to Press Releases ACT nurses look to improve management of childhood diabetes by Australian families and clinicians

Lilly
ACT nurses look to improve management of childhood diabetes by Australian families and clinicians

Thursday 14 September, 2006: A grant from this year's Eli Lilly Diabetes Research Grant Program has been awarded to a team of diabetes nurse educators from the Australian Capital Territory to further educate children and their parents about the best way to manage diabetes.

Ms Di Roberts, Clinical Nurse Consultant Paediatric and Adolescent Diabetes, and Ms Wendy Mossman, Credentialed Diabetes Educator, both from the ACT Diabetes Service, have been awarded a grant of $8,000 to conduct research into the treatment of hypoglycaemia (low blood glucose level) in children with Type 1 Diabetes.

"Hypoglycemia is something every child with diabetes can expect to face. Our controlled study will investigate the benefits to families of self treating hypoglycemia at home in children between the age of five and twelve," said Ms Mossman.

"We hope to show that self management of hypoglycemia can help prevent blood glucose problems and related issues like excessive weight gain."

Eli Lilly will this year contribute over $170,000 in research funding.

"The Lilly Diabetes Research Grants demonstrate our long-standing commitment to the improvement of diabetes education and care across the world, and provide an opportunity to recognise the good work of people in individual communities," said Eli Lilly Managing Director Stephen Fry.

"Eli Lilly's commitment has extended to the contribution of $1.42 million to support independent research into diabetes since 2000.

"Diabetes is a chronic, debilitating and sometimes fatal condition that impacts more than five percent of Australians. It is important that we recognise the contribution of those people in the community who work tirelessly to reduce the impact on diabetes on the lives of others," said Mr Fry.

Lilly's Leadership in Diabetes
Through a long-standing commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has been the industry leader in pioneering therapies to help health care professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients.

About Eli Lilly and Company
In Australia, Lilly is a leading research-driven pharmaceutical company, specialising in discovery, development and marketing of medicines for prevention and treatment of human disease.

Lilly's pipeline is one of the strongest in the industry and has the potential to address many serious unmet medical needs of people worldwide. In the last decade, Lilly has introduced important new drugs for the treatment of cancer, schizophrenia, osteoporosis, diabetes, cardiovascular complications and most recently severe sepsis.

Lilly supports research and development in Australia through alliances with some of the country's foremost biotechnology companies, medical research institutions and universities.

# # #


Issued by Palin Communications on behalf of Eli Lilly.
For further information please contact Gareth Finch (0409 747 157) or Karina Candia (0402 307 056) on 02 9420 1387.



                 
  Home Return to Top

Last Updated: Wednesday November 05, 2014 21:27:32
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2015. Comments and Feedback.